Posted by Michael Wonder on 25 May 2021
Scholar Rock receives fast track designation from the U.S. FDA for apitegromab for the treatment of patients with spinal muscular atrophy
24 May 2021 - Builds on Priority Medicines (PRIME) designation recently granted by the EMA recognising the unmet medical needs of patients with spinal muscular atrophy.
Scholar Rock today announced that the U.S. FDA has granted fast track designation for apitegromab, a selective inhibitor of myostatin activation, for the treatment of patients with spinal muscular atrophy.
Read Scholar Rock press release
